{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001439222","name":"AGIOS PHARMACEUTICALS, INC.","summary":"Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare disease treatment, with a foundation in hematology and cellular metabolism. Its lead product, mitapivat (PYRUKYND/AQVESME), is a pyruvate kinase activator approved for PK deficiency and thalassemia. The pipeline includes tebapivat (LR-MDS, SCD), AG-181 (PKU), and AG-236 (polycythemia vera), an siRNA licensed from Alnylam Pharmaceuticals.","people":[],"products":[{"name":"PYRUKYND (mitapivat)","type":"service","description":"PK activator approved for PK deficiency (US, EU, Great Britain) and thalassemia (US, Saudi Arabia); treats hemolytic anemia."},{"name":"AQVESME (mitapivat)","type":"service","description":"Brand name for mitapivat approved in the US for anemia in adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia."},{"name":"Tebapivat","type":"service","description":"Novel PK activator in development for lower-risk myelodysplastic syndromes and sickle cell disease."},{"name":"AG-181","type":"service","description":"Phenylalanine hydroxylase stabilizer in development for phenylketonuria (PKU)."},{"name":"AG-236","type":"service","description":"siRNA licensed from Alnylam targeting TMPRSS6 gene, in development for polycythemia vera."}],"partnerships":[{"partner_name":"Alnylam Pharmaceuticals, Inc.","partnership_type":"licensing","description":"Agios licensed AG-236, a novel preclinical siRNA targeting TMPRSS6, for development and commercialization in polycythemia vera; up-front payment made in 2023 with milestones and royalties.","start_date":null},{"partner_name":"Servier Pharmaceuticals, LLC","partnership_type":"strategic","description":"Agios sold its oncology business to Servier in March 2021 for ~$1.8 billion, retaining contingent payments including a vorasidenib milestone and royalty rights.","start_date":null},{"partner_name":"Royalty Pharma Investments 2019 ICAV","partnership_type":"strategic","description":"Agios sold Vorasidenib Royalty Rights to Royalty Pharma for $905 million in August 2024, retaining a 3% earn-out on US net sales above $1 billion per year.","start_date":null}],"affiliations":[],"origin":{"leaf":"359db0b3751162e6f30bebbd21d74265b8cfc5c9fca5885e837af80f171f27dd","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"e6e522847c9a67885363cf79024e79780003f101fbca1ab865ba1a864e9e7083","parent":"a0e797e5c1ae146bb7ff0b18daa68e4ed860a3106bba650ada2d50479e38d393","source":"0001439222-26-000025","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}